Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for ALTO-207 in Treatment resistant depression (TRD). The expected timing is based on the latest available company guidance and may change.
10/20/25- Initiate Ph2b trial by mid-2026. Initiate Ph3 study by early 2027 following readiness work and alignment with FDA. 11/12/25:- On track for Ph2b TRD initiation in H1 2026 and Ph3 trial by early 2027. 03/16/26:- Ph2b TRD initiation still expected 1H 2026; topline Ph2b data planned 2H 2027. 04/21/26:- Ph2b TRD trial initiated; topline data expected in H2 2027. 05/04/26:- Ph2a MDD data positive. Ph2b TRD ongoing; titration adjusted; topline still expected H2 2027. 05/13/26:- Ph2b TRD trial ongoing; Ph3 TRD initiation expected early 2027; Ph2b topline still guided 2H 2027. 08/12/26:- PACE-3 Ph3 monotherapy trial added. PACE-2 Ph3 initiation is expected Early 2027; PACE-1 topline data and PACE-3 initiation are expected H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.